HTG Molecular to Present a Corporate Overview at the H.C. Wainwright 20th Annual Global Investment Conference
HTG Molecular Diagnostics, Inc.
Aug. 30, 2018
TUCSON, Ariz., Aug. 30, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a provider of instruments, reagents, and services for molecular profiling applications, today announced that TJ Johnson, Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 20th Annual Global Investment Conference, being held September 4-6, 2018 at the St. Regis Hotel in New York City.
HTG Molecular Diagnostics Presentation Details Date: Thursday, September 6 Time: 1:45pm Eastern Time Location: The St. Regis New York, Louis XVI
About HTG: HTG is focused on next generation sequencing (NGS) based molecular profiling. The company’s proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. HTG’s customers use its technology to identify biomarkers important for precision medicine, to understand the clinical relevance of these discoveries, and ultimately to identify treatment options. Our mission is to empower precision medicine at the local level.
Ashley R. RobinsonLifeSci Advisors, LLCPhone: (617) 525-7754Email: firstname.lastname@example.org
TJ Johnson Chief Executive Officer HTG Molecular Diagnostics Phone: (520) 547-2827 x130 Email: email@example.com